GlassScriptPhysician profile
Shanti Thomas
NPI 1083707111
$4,055.61
in general payments reported to CMS, 2019-2025
45 companies · $973 in 2025
The $973 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $55.54 · 2021: $442 · 2022: $342 · 2023: $447 · 2024: $1,259 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,977 · Education: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.88 |
| Education | $702.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $350.76 | 2019-2025 | Tecentriq, Polivy, Alecensa |
| Novartis Pharmaceuticals Corporation | $345.64 | 2019-2025 | |
| Daiichi Sankyo INC. | $256.01 | 2019-2025 | Enhertu, Vanflyta |
| Gilead Sciences, INC. | $254.82 | 2019-2025 | Trodelvy |
| Sanofi-Aventis U.S. LLC | $248.93 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.20 | 2019-2025 | Fruzaqla, Alunbrig |
| Celgene Corporation | $141.20 | 2019-2024 | Pomalyst, Reblozyl |
| Eisai INC. | $140.03 | 2022-2025 | |
| Seagen INC. | $135.81 | 2021-2023 | Padcev |
| Pfizer INC. | $135.26 | 2019-2025 | |
| Abbvie INC. | $134.65 | 2023-2024 | Venclexta |
| Aveo Pharmaceuticals, INC. | $130.79 | 2024-2025 | |
| Lilly USA, LLC | $128.16 | 2019-2021 | |
| Astellas Pharma US INC | $116.19 | 2019-2024 | Padcev, Xtandi |
| Incyte Corporation | $112.88 | 2019-2025 | Jakafi |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $106.63 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Boston Scientific Corporation | $90.50 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Janssen Biotech, INC. | $80.72 | 2024-2025 | Carvykti, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $72.00 | 2019-2025 | Enhertu |
| Stemline Therapeutics INC. | $56.81 | 2024-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $53.90 | 2025 | Orgovyx |
| Merck Sharp & Dohme LLC | $53.56 | 2019-2025 | Lynparza, Keytruda |
| Jazz Pharmaceuticals INC. | $47.05 | 2019 | |
| Taiho Oncology, INC. | $44.53 | 2019-2024 | |
| Genzyme Corporation | $42.58 | 2019-2022 | |
| Emd Serono, INC. | $42.01 | 2019-2024 | |
| Tersera Therapeutics LLC | $41.84 | 2023-2024 | Zoladex |
| Pharmacosmos Therapeutics INC. | $40.83 | 2021 | |
| Pharmaessentia USA Corporation | $35.70 | 2022 | |
| Exelixis INC. | $35.54 | 2019 | |
| Karyopharm Therapeutics INC. | $34.97 | 2023 | Xpovio |
| Glaxosmithkline, LLC. | $33.98 | 2024-2025 | Ojjaara |
| Servier Pharmaceuticals LLC | $30.51 | 2023-2024 | |
| Tempus Ai, INC | $29.60 | 2024 | |
| Beigene USA, INC. | $25.82 | 2024 | Tevimbra |
| Blueprint Medicines Corporation | $25.13 | 2025 | Ayvakit |
| Array Biopharma INC | $23.44 | 2024 | Mektovi, Lorbrena, Braftovi |
| Sobi, INC | $23.17 | 2025 | |
| Genmab U.S., INC. | $23.13 | 2025 | Epkinly |
| Beone Medicines USA, INC. | $21.41 | 2025 | Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $21.10 | 2025 | |
| Puma Biotechnology, INC. | $16.41 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.60 | 2019 | |
| Verastem, INC. | $15.17 | 2019 | |
| Fortovia Therapeutics, INC. | $14.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanti Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.